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In this study, we determined the efficacy of various dosing regimens for erythromycin and azithromycin
against four pneumococci with different susceptibilities to penicillin in an in vitro pharmacokinetic model and
in a mouse peritonitis model. The MIC was 0.03 mg/ml, and the 50% effective doses (determined after one dose)
of both drugs were comparable for the four pneumococcal strains and were in the range of 1.83 to 6.22 mg/kg.
Dosing experiments with mice, using regimens for azithromycin of one to eight doses/6 h, showed the one-dose
regimen to give the best result; of the pharmacodynamic parameters tested (the maximum drug concentration
in serum [Cmax], the times that the drug concentration in serum remained above the MIC and above the
concentration required for maximum killing, and the area under the concentration time curve), Cmax was the
best predictor of outcome. The bacterial counts in mouse blood or peritoneal fluid during the first 24 h after
challenge were not correlated to survival of the mice. The serum concentration profiles obtained with mice for
the different dosing regimens were simulated in the in vitro pharmacokinetic model. Here as well, the one-dose
regimen of azithromycin showed the best result. However, the killing curves in vivo in mouse blood and
peritoneal fluid and in the vitro pharmacokinetic model were not similar. The in vitro killing curves showed
a decrease of 2 log10 within 2 and 3 h for azithromycin and erythromycin, respectively, whereas the in vivo
killing curves showed a bacteriostatic effect for both drugs. It is concluded that the results in terms of predictive
pharmacodynamic parameters are comparable for the in vitro and in vivo models and that high initial
concentrations of azithromycin favor a good outcome.
Although macrolides are being used to treat moderate to
severe infections, it is not well known how effective these drugs
are in the treatment of infections that are accompanied by a
severe sepsis syndrome (5, 9, 11, 14, 15, 24, 26). One of the
problems is that the volume of distribution of these drugs is
quite large, resulting in relatively low concentrations in serum
(10, 18, 22). Thus, the relationship between the concentration
in serum and the MIC for the infecting microorganism never
attains high values and remains questionable. This is especially
true for the recently clinically introduced 15-membered mac-
rolide the azalide azithromycin, which has an even greater
volume of distribution. For example, the range of azithromycin
concentrations in tissue is 1 to 9 mg/kg, which is 10 to 100 times
the concentration in serum (6, 7, 30). The importance of the
high ratio of the concentration in serum to the MIC has not
been established for azithromycin. Since the occurrence of
penicillin resistance in pneumococci (16), the quest for knowl-
edge about the efficacy of alternative drugs in the treatment of
pneumococcal disease is warranted.
There are several ways to shed light on this issue by using a
mouse sepsis model, the survival of mice or the bacterial
counts can be determined, and by measuring the concentra-
tions of the macrolides in the different body compartments, the
relationship between drug concentration and efficacy can be
determined. Although this approach has been used in several
animal models, in none of these models was a severe sepsis
syndrome present (1, 3, 23, 29). Another approach would be to
simulate the pharmacokinetics of the macrolides in an in vitro
pharmacodynamic model and determine the antimicrobial ef-
ficacy of macrolides given in several dosing regimens. By com-
bining the results of in vitro and in vivo efficacy experiments,
more detailed insight into the pharmacodynamic principles of
macrolides can probably be gained. Such a combined approach
would also be of value when defining breakpoints for in vitro
susceptibility testing with routine laboratory tests. However,
the usual method of relating MICs directly to concentrations in
serum can obviously be applied to macrolide drugs only within
certain limits.
The purpose of the present study was twofold. The first goal
was to investigate the efficacy of one of the recently clinically
introduced macrolides, azithromycin, in the treatment of a
severe sepsis syndrome and to determine which pharmacoki-
netic and pharmacodynamic parameters are the best predictors
of efficacy.
The second objective of the study was to compare data
derived from an animal infection model with those determined
in an in vitro pharmacodynamic model. There is, as far as we
know, only one previous study comparing the results of an in
vitro model with those of an animal model (2). However, in
that study, efficacy, as measured by the killing effect, was com-
parable in both models but macrolides were not used.
(This report was presented at the 36th International Con-
ference on Antimicrobial Agents and Chemotherapy 1996 in
New Orleans, La. [poster A-048].)
MATERIALS AND METHODS
Strains, antibiotics, and media. The strains used for the experiments were four
clinical isolates of Streptococcus pneumoniae with different susceptibilities to
penicillin. The serotypes were determined at The Streptococcus Department,
Statens Serum Institut (Copenhagen, Denmark), by using anticapsular polysac-
charide antibodies (19). Erythromycin (E 6376; Sigma Chemical Company, St.
Louis, Mo.) and azithromycin (azithromycin dihydrate; Pfizer Pharmaceuticals,
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Ringasskiddy, Ireland) were used and dissolved in accordance with the manu-
facturers’ instructions. All in vitro experiments were performed in Mueller-
Hinton broth (MHB; Difco, Amsterdam, The Netherlands). Todd-Hewitt broth
(Difco) was used to culture pneumococci prior to the time-kill experiments, and
beef broth (Statens Serum Institut) was used as the medium for pneumococcal
cultures prior to mouse experiments. All experimental samples were plated on
5% blood agar plates (Sanofi Pasteur [Maassluis, The Netherlands] and Statens
Serum Institut).
MICs, generation time, and conventional time-kill curves. MICs of erythro-
mycin and azithromycin were determined by using a standard agar dilution
method (21), a macrodilution method (21), and the gradient disk diffusion
method (E test; AB Biodisk, Solna, Sweden). The generation times of all strains
were determined during conventional logarithmic growth in tubes of MHB.
Conventional time-kill experiments were performed with erythromycin and
azithromycin at concentrations of 0, 0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, and 128 times
the MIC in shaking tubes containing 10 ml of MHB. All time-kill curves were
determined in duplicate. For each experiment, a fresh culture was made in 30 ml
of Todd-Hewitt broth inoculated with 5 3 105 CFU of a standardized pneumo-
coccal batch stored at 280°C. After 12 h of incubation at 37°C, these cultures
were diluted in prewarmed MHB and shaken for 1.5 h at 37°C, resulting in a
logarithmic-phase culture of 5 3 105 CFU/ml. Samples were then diluted with
prewarmed MHB containing twice the final antibiotic concentration. Samples
were subsequently taken at t 5 0, 1, 2, 4, and 6 h, and the numbers of CFU per
milliliter were determined after making appropriate 10-fold dilutions in cold
phosphate-buffered saline (pH 7.4). From each dilution, 0.1 ml was plated on a
5% blood agar plate and incubated for 48 h at 37°C (limit of detection, 10
CFU/ml).
Mouse peritonitis model. All animal experiments were approved by the animal
ethical committee. The model was previously described in detail (17). Briefly,
outbred female ssc:CF1 mice (age, approximately 8 weeks; weight, 30 6 2 g) were
used throughout the study. The mice were kept at five per cage and had free
access to chow and water. From fresh overnight cultures on 5% blood agar
plates, an inoculum was prepared immediately before inoculation by suspending
colonies in sterile beef broth medium and diluting it to a suspension containing
approximately 2 3 106 CFU/ml. Mucin (M-2378; Sigma Chemical Company) was
used as an adjuvant for inoculation of the mice. Immediately before inoculation,
the mucin solutions were diluted 1:1 with the pneumococcal suspensions, yielding
a final mucin concentration of 5% (wt/vol). The final number of CFU per
milliliter in the inoculum was determined by plating on 5% blood agar. Inocu-
lation was performed by intraperitoneal injection of 0.5 ml of the inoculum.
Blood samples were obtained by cutting the axillary artery after anesthetizing the
mice with CO2. After the mice were sacrificed, peritoneal washes were per-
formed by intraperitoneal injection of 2 ml of sterile saline, and after the abdo-
men was massaged, the peritoneum was opened for fluid collection (8). Blood
and peritoneal fluids were immediately diluted, and duplicate 20-ml samples were
plated in spots on 5% blood agar plates. Mice were treated by administering
subcutaneous injections in the neck region.
Determination of the ED50. The 50% effective doses (ED50s) were determined
by administration of one-dose treatments 1 h after challenge with pneumococci.
The determinations were done in two steps for each drug and strain. In the first
step, 25 mice were treated in groups of 5 with five successive 10-fold higher doses
of the antibiotics. The maximum dose was 100 mg/kg. In the second step, 25 mice
were treated in groups of 5 with doses within the range of the ED50s estimated
in the first step. A group of five control mice was included in every experiment.
The drugs were administered as a single injection of 0.5 ml subcutaneously. The
mice were observed for 6 days, and mortality was registered.
Pharmacokinetics in mice. Pharmacokinetic studies of erythromycin and
azithromycin in healthy mice were performed. For each time point, blood was
collected from three mice for determination of the antibiotic concentration.
After collection of the samples, the blood was centrifuged at 1,630 3 g for 10 min
and the serum was stored at 280°C until analysis. The cup plate or the disk
diffusion bioassay method (4) was used to measure the concentrations of eryth-
romycin and azithromycin in mouse serum. Sarcina lutea ATCC 9341 was used
for the bioassay. The lower limit of detection was 0.125 mg/ml. The variation
coefficients were below 5% for all of the bioassays used. All determinations were
performed in duplicate.
Dose regimens for mice. The treatments were always initiated 1 h after chal-
lenge, a time at which the bacteria were known to be in the growth phase (17).
The total dose of either erythromycin or azithromycin was 4 mg/kg, given either
as one dose or divided into four doses of 1 mg/kg, with a dosing interval of two
serum elimination half-lives (t1/2s) (t 5 0 and 80 min and t 5 0 and 100 min,
respectively). These regimens were chosen because of the difference between the
t1/2s of the two drugs and the fact that we wanted to obtain comparable regimens
for the drugs. In mouse survival studies, the same dose of 4 mg/kg was given as
one, two, four, or eight doses of azithromycin (i.e., 4, 2, 1, and 0.5 mg/kg,
respectively), with dose intervals of 4, 2, and 1 times the t1/2, respectively.
Erythromycin was given once or as four doses with an interval of twice the t1/2.
A group of control mice was included in every experiment.
In vitro model. The in vitro model used was described previously in detail (20).
Briefly, a two-compartment model consisting of one central compartment and
FIG. 1. Growth and killing of S. pneumoniae 1064 exposed to increasing
concentrations of erythromycin (top) or azithromycin (bottom). The change in
log CFU is the difference in CFU at t 5 0 h and at 1 h (h) or 4 h (E),
respectively. The symbols indicate the observed CFU, and the curves are fits
obtained by using a sigmoidal dose-response equation with a variable slope. The
data are means of two separate experiments.
TABLE 1. In vivo and in vitro efficacies of azithromycin and erythromycin against four S. pneumoniae strains
Strain/
serotype
MIC (mg/ml) ED50 (mg/kg) (95% CI)a Generation time
(min) in MHB
in vitroAzithromycin Erythromycin Penicillin Azithromycin Erythromycin
68040/6B 0.03 0.03 0.016 1.83 (0.34–4.90) 3.75 (1.27–8.28) 53
964/14 0.03 0.03 0.25 3.87 (1.49–8.10) 3.48 (0.54–13.55) 44
999/19A 0.03 0.03 0.5 6.22 (2.95–12.97) 4.15 (1.18–10.51) 31
1064/6B 0.03 0.03 0.25 4.84 (4.84–4.84) 2.15 (0.37–6.04) 31
a ED50s were determined in mice. CI, confidence interval.
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four peripheral compartments consisting of disposable dialyzer units (ST23;
Baxter, Utrecht, The Netherlands) was used to expose the bacteria in the pe-
ripheral compartments to declining antibiotic concentrations that vary according
to mouse pharmacokinetics. One hundred fifty milliliters of a logarithmic-phase
culture containing 5 3 105 CFU/ml (prepared freshly as described above) was
injected into the peripheral compartments of the in vitro model. Samples were
taken at the intervals indicated in Results for determination of CFU counts and
antibiotic concentrations. The peak concentrations (Cmax), the time to the Cmax
(Tmax), and the t1/2 of the antibiotics in the model were adjusted to those found
in the mouse model. Antibiotic treatment was started at t 5 0 h with an infusor
(Braun AG, Melsungen, Germany).
Dose regimens in vitro. The erythromycin and azithromycin regimens used for
the mice were simulated in the in vitro model (see above). Samples were taken
every hour starting at t 5 0 h. At 10 and 20 min after the Cmax was reached,
additional samples were taken for antibiotic concentration determination. Anti-
biotic concentrations were determined by using the cub agar diffusion method as
described above. These concentrations were used to check the Cmax and t1/2. All
regimens were performed in quadruplicate.
Analysis and statistical methods. The logit transformation was used to calcu-
late the ED50 (27). The t1/2s of erythromycin and azithromycin in mice and in the
vitro model were estimated from the expression 2log 2/b, where b is the slope
of the serum elimination regression line (time versus the log of the concentration
in serum). From the conventional time-kill curves, the minimum concentrations
of the drugs given the maximal achievable killing of the pneumococcus were
defined. The Cmax, the Tmax, and the times that the drug concentration in serum
remained above the MIC (T.MIC) and above the concentration required for
maximum killing (T.max-kill) were estimated from the serum elimination regres-
sion line. A simulation of the antibiotic concentration profile during all experi-
ments was done by using the formula of an open-compartment model after
extravascular administration (25). The area under the concentration-time curve
(AUC), T.MIC, and T.max-kill (i.e., time above a concentration equivalent to four
times the MIC) were calculated by using these simulated curves.
The Hill equation with a variable slope was used to describe the dose-response
curves of the conventional time-kill experiments. Statistical analysis of the bac-
terial killing curves (i.e., the difference between log10 CFU per milliliter at t 5 0 h
and t 5 6 h), both for the in vitro model and for the conventional killing curves,
was done by two-way analyses of variance and Tukey’s test for multiple compar-
isons of significance (13).
The method of Kaplan-Meier (12) was used for evaluation of the survival data
with product limit survival estimates. The log rank test was used to determine
significant trends in the curves (12).
To determine which pharmacokinetic parameters are predictive of efficacy,
multivariance analyses were performed by using forward and backward elimina-
tion procedures (27). The following parameters were included in the model:
Cmax, Tmax, Tmax-kill, and AUC. A P value of #0.05 (two tailed) was considered
significant.
RESULTS
MICs and ED50s. The capsular serotypes and in vitro gen-
eration times of the four clinical isolates of S. pneumoniae
tested are given in Table 1, as are the MICs and the ED50s of
azithromycin and erythromycin. The MICs were identical for
all four strains and with all three of the methods used (data not
shown), and the ED50s for mice were also highly comparable.
Conventional time-kill experiments. Results of time-kill
experiments with strain 1064 exposed to azithromycin and
FIG. 2. Killing of S. pneumoniae 1064 in mice and in the in vitro model. Control data on the growth of the strain in vitro (3) and in the blood (—3—) and
peritoneums (---3---) of mice are shown in all of the graphs. The symbols correspond to exposure to erythromycin in one dose (n) or in four divided doses ({). For
the in vivo experiments, curves indicated by solid and broken lines indicate the numbers of CFU in blood and the peritoneum, respectively.
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erythromycin in vitro are given in Fig. 1. The change in log10
CFU per milliliter was plotted against the concentrations as
multiples of the MIC and then fitted to the Hill equation.
The curves fitted to the counts obtained after 4 h of expo-
sure show that maximum killing was reached at four times
the MIC. In contrast, if 1-h exposure values are used, max-
imum killing by azithromycin was reached only at 128 times
the MIC, indicating that there is concentration-dependent
killing if strains are only briefly exposed to the drug. This
phenomenon was not observed with strain 964; otherwise,
the results were similar to those obtained with strain 1064
(data not shown).
Pharmacokinetics in mice and in the in vitro model. The
Tmax, Cmax, and t1/2 (mean 6 standard deviation) determined
with mice for azithromycin and erythromycin were 10 to 20
min, 0.8 to 1.0 mg/ml, and 43 6 8 and 51 6 10 min, respectively.
On the basis of these observations, the pharmacokinetic pro-
files of the free fractions of these drugs were simulated in the
in vitro model. The Cmax in the model was adjusted to 0.8
mg/liter for both drugs, taking into account approximately 20%
protein binding for erythromycin and ,8% for azithromycin
(28). There were no significant differences between the ob-
served relevant pharmacokinetic parameters in vivo and in
vitro. The actual drug concentrations determined during the
experiments fitted well in the simulated drug-time profile for
all regimens (data not shown).
Efficacy studies. (i) CFU counts. In mice, the efficacy of a
4-mg/kg dose of azithromycin or erythromycin, administered
either in one dose or in divided doses, was determined by CFU
counts in blood and in peritoneal fluid taken at intervals of up
to 6 h. The number of CFU in blood generally followed the
same time course as that found in peritoneal fluid (Fig. 2).
Erythromycin had only a slight bactericidal effect both in blood
and in the peritoneum, as was true for azithromycin as well. At
t 5 6 h, no significant difference between the two dose regi-
mens of either macrolide could be demonstrated.
When the same dosing regimens were used in the pharma-
cokinetic model, there was no apparent difference between the
one-dose regimen of erythromycin and the same dose divided
into four doses. In contrast, for azithromycin the one-dose
regimen was significantly more efficacious than the four-dose
regimen (P 5 0.02). This difference became apparent after the
first hour of exposure.
Comparison of the data for erythromycin and azithromycin
showed better in vitro killing by azithromycin given as one dose
than by one dose of erythromycin (P 5 0.01). However, no
significant difference in efficacy was observed between the
other azithromycin and erythromycin dosing regimens. Exper-
iments with strain 964 showed similar results (data not shown).
(ii) Pharmacodynamics in mice versus in vitro. The survival
rates of mice observed for 6 days after treatment with the
different regimens showed that there was a difference in effi-
cacy between the different dosing regimens of azithromycin
(Table 2). Kaplan-Meier survival analysis showed that there
was a trend for increased survival when azithromycin was ad-
ministered less frequently (P 5 0.001). In contrast, survival of
mice was not different for the erythromycin regimens (P 5
0.83).
The correlation between survival of mice and bacterial
counts was studied during the dosing experiments. We did not
find any correlation between survival of mice and bacterial
counts either in blood or in peritoneal fluid. In one of the
experiments, the counts were measured during the treatment
period (Table 2). In another of these dosing experiments, the
counts were determined in five mice from each treatment
group 24 h after challenge. The results, given as log10 counts in
blood and peritoneal fluid, as medians and ranges, and the
6-day survival of mice treated equally, are shown in Table 3.
There was no significant correlation between bacterial killing
at t 5 24 h and survival of mice.
To determine which of the pharmacodynamic parameters
(AUC, T.MIC, Cmax, or T.max-kill) was most predictive of the
outcomes of the different azithromycin regimens in vivo and in
vitro, a multivariance analysis was performed, despite the few
data sets. Both for survival and for killing in the in vitro model,
the Cmax appeared to be the most significant predictive param-
eter ([P 5 0.001] and R2 5 0.49 [P 5 0.003], respectively). In
the in vitro model, the coefficients of determination for the
other pharmacodynamic parameters had R2 values of 0.10 (P 5
0.24), 0.35 (P 5 0.015), and 0.40 (P 5 0.009) for T.max-kill,
AUC, and T.MIC, respectively. For the survival experiment,
the P values of the survival analysis were 0.006 and 0.072 for
T.max-kill and T.MIC, respectively. For the AUC, no calcula-
tions were possible in vivo since we used only one dose. For
erythromycin, such an analysis was not possible due to the
smaller number of dosing regimens tested.
TABLE 2. Survival of mice challenged with S. pneumoniae 1064 and pneumococcal killing effects of erythromycin and azithromycin in vivo
and in vitro
No. of dosesa
In vivo data
In vitro change
in log CFU at
6 h (95% CI)
Pharmacokinetic parametersb
No. of mice
dead/total
(%) within
6 days
Change in log CFU at 6 h in
blood/peritoneal fluid (95% CI)c
Cmax
(mg/liter)
(3 MIC)
T.MIC
(h)
T.max-kill
(4 3 MIC)
(h)
AUC0–6
(mg/liter z h)
AUC0–`
(mg/liter z h)
Azithromycin
1 37/85 (44) 0.5 (0.4 to 21.3)/0.02 (21.3 to 1.3) 22.4 (2.8–2.1) 0.8 (26) 4.2 2.5 1.2 1.2
2 29/54 (54) NDd 21.6 (2.0–1.3) 0.4 (13) 6.9 3.6 1.2 1.2
4 30/55 (55) 0.5 (0.5 to 0.5)/20.6 (22.8 to 21.6) 21.6 (2.3–0.9) 0.2 (6.5) 7.5 3.2 0.9 1.2
8 41/55 (75) ND 21.6 (1.7–1.5) 0.1 (3.3) 7.5 0 0.6 1.2
Erythromycin
1 24/30 (80) 20.2 (20.5 to 0.1)/21.2 (24.9 to 20.8) 21.9 (2.2–1.9) 0.8 (26) 3.2 2.0 1.0 1.0
4 24/30 (80) 20.9 (21.6 to 20.2)/21.2 (22.2 to 20.2) 22.3 (2.5–2.1) 0.2 (6.5) 6.4 3.6 1.0 1.0
a The total amount of each drug given in each case was 4 mg/kg.
b Calculated from simulated curves.
c CI, confidence interval.
d ND, not done.
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DISCUSSION
In this study, we evaluated the pharmacodynamic parame-
ters of efficacy for macrolide antibiotics (azithromycin and
erythromycin) in a mouse model of a severe sepsis syndrome
due to bacteremial pneumococcal infection and compared
these with the same parameters in an in vitro pharmacokinetic
model. In both models, the azithromycin Cmax was most pre-
dictive of success, indicating that large doses given infrequently
are better than the same amount of the drug given in multiple
doses with shorter dosing intervals.
The results of the conventional in vitro time-kill experiments
indicate that the maximum bactericidal effect of azithromycin
is reached at four times the MIC. However, there appears to be
a greater concentration-dependent effect during the first hour
of exposure to azithromycin. This effect disappears after 1 to
4 h. One of the explanations could be that there is some kind
of concentration-dependent uptake of azithromycin in the cell.
If this is the case, it could be argued that the first dose of
azithromycin should be high. On the other hand, the maximum
effect after 1 h is only 1 log10 decrease whereas a 2 log10
decrease is achieved after 4 h; thus, the net initial effect of a
high first dose would probably be marginal.
The killing experiments performed with the in vitro phar-
macokinetic model showed a significantly better result when
azithromycin was given as one dose than when it was given in
a multiple-dose regimen. This benefit of one dose became
apparent during the first hour of exposure (Fig. 2). We calcu-
lated that the Cmax reached during the one-dose experiment
corresponds to 16 to 32 times the MIC. Beyond 1 h, the kinet-
ics of killing more or less paralleled that of the other dosing
regimens, which contrasted with the progressive killing ob-
served in the conventional time-kill experiments. This differ-
ence can be explained by the decreasing concentrations of
azithromycin in the pharmacodynamic model, as opposed to
the static concentrations in the conventional killing experi-
ments.
In vivo, the initial effects of azithromycin on the CFU counts
in blood and the peritoneum were quite similar, irrespective of
the dosing regimen. There was no obvious relationship with in
vivo efficacy and the data obtained with the in vitro model. An
explanation could be that the pneumococcal growth rates are
significantly different in the two systems.
Comparison of bacterial killing in vitro and in mice showed
significant differences both during the 6 h of treatment and
24 h after challenge. The same factors as just mentioned to
explain the in vivo results may be responsible for this. One way
to obtain more comparable results would be to reproduce the
exact in vivo growth rate of pneumococci in the in vitro model,
for instance, by adjusting the composition of the medium.
Another possibility is to compare killing curves obtained with
the in vitro and in vivo models after correcting for differences
in the rate of growth. In this case, the observed difference
between in vitro and in vivo killing by azithromycin disappears
(results not shown). Although this approach seems attractive,
the results may become highly dependent on differences in
growth rate and may poorly reflect the antimicrobial activity of
the agent itself. We conclude that initial bacterial killing rates
obtained with the two models are not directly comparable.
The results of the mouse survival experiments showed that
azithromycin administered as one dose significantly increased
the survival rate compared with all of the other regimens.
Furthermore, trend analysis showed that survival was inversely
related to the number of divided doses given. This indicates
that the Cmax may be an important pharmacodynamic param-
eter for prediction of clinical efficacy. Other pharmacodynamic
parameters did not show such a consistent relationship with
survival. These results are in agreement with those obtained
from the pharmacodynamic model, as regression analysis of
the in vitro results likewise showed the Cmax to be the single
significant parameter that explains the efficacy of azithromycin.
Thus, although the initial (6-h) killing rates obtained with
the two models are not directly comparable, the final conclu-
sion with regard to the pharmacodynamics of azithromycin are
the same. This was also shown for another in vitro and in vivo
model comparison using other antibiotics (2).
The data for the two erythromycin regimens tested (Table 2)
showed no significant difference in either the survival data or
the killing data from the in vitro model.
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